Nomura Holdings, Inc. Sponsored ADR Aktie News

Nomura Holdings, Inc. (NYSE:NMR ) Q4 2024 Earnings Conference Call April 26, 2024 5:30 AM ET Company Participants Takumi Kitamura - Chief Financial Officer Conference Call Participants Masao Muraki - SMBC Nikko Securities Wataru Otsuka - SBI Securities Kazuki Watanabe - Daiwa Securities Koichi Niwa - Citi Operator Good day, everyone, and welcome to today's Nomura Holdings Fourth Quarter and Ful...

Nomura Holdings' Americas market has the potential to be a key growth engine for the company in the long run. My preview of NMR's future financial performance suggests that its Q4 FY 2024 results announcement in late-April could be a positive surprise. I still rate Nomura Holdings stock as a Buy, following an assessment of the company's prospects for the near term and long run.

S&P 500 and Nasdaq Composite have seen gains of around 2% and 3% respectively in the first month of 2024

Nomura Holdings, Inc. (NMR) Q3 2024 Earnings Call Transcript

NMR's latest quarterly top line and bottom line were better than what the sell-side analysts had forecasted previously. Nomura revealed a new share repurchase program which suggests that the company has the intention to spend a maximum of JPY100 billion on share buybacks in the next couple of months. I upgraded my rating for NMR to a Buy, as I think that Nomura can improve its ROE to 8% or high...

Nomura Holdings, Inc.'s ability to meet its 2025 ROE goal is uncertain. But Nomura Holdings is a play on the expansion of Japan's investor base in the future in tandem with an increase in financial literacy. A Hold rating for Nomura stock is fair, as I think that it is premature to turn bullish on the stock now.

Nomura Holdings said on Thursday it is reassessing its mainland China business, as losses mount at its Shanghai-based securities joint venture in another blow to the top Japanese investment bank's global expansion strategy.

Nomura Holdings' Q1 FY 2024 ROE was low at 2.9%, which is way below the company's FY 2025 ROE target at the 8%-10% level. NMR is valued by the market at an undemanding 0.55 times P/B, which is reasonable considering that the company has found it tough to achieve a higher ROE. I stick to my existing Hold rating for Nomura; I will only consider upgrading NMR's rating to a Buy if there are signs o...